Study Number	Completed Clinical Trial Report Summaries
D2451C00001	A Multicenter, Multinational, Open-Label Study of the Efficacy, Safety, and Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to <17 Years of Age
D2451C00261	A Dose-Ranging and Safety Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 6 to <17 Years of Age: A 4-Week, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
SH-AHM-0040 (AM231)	Evaluation of The Antihypertensive Efficacy of Candesartan Cilexetil in Comparison to Losartan: AMulticenter, Double-blind, Randomized, Parallel-group, Forced-titration Study.
SH-AHM-0039 (AM230)	Evaluation of the Antihypertensive Efficacy of Candesartan Cilexetil in Comparison to Losartan: A Multicenter, Double-blind, Randomized, Parallel-group, Forced-titration Study.
SH-AHM-0032 (AM205)	Evaluation of the Efficacy and Tolerability of Candesartan Cilexetil in Hypertensive Patients Across Several Aspects of Patient Demographics.
SH-AHM-0016	The effect duration of Candesartan Cilexetil (8-16 MG) once daily, in comparison with Enalapril (10-20 MG) once daily, in patients with mild to moderate hypertension.
SH-AHM-0013	Comparison between candesartan cilexetil 16mg and lisinopril 20mg and their combination in patients with type II diabetes mellitus and microalbuminuria.- CALM Study.
SH-AHM-0011	Study on cognition and prognosis in elderly (SCOPE)
SH-AHS-0007	Candesartan cilexetil (candesartan) in heart failure assessment of reduction in mortality and morbidity (CHARM) Study of candesartan in patients with heart failure and preserved left ventricular systolic function (CHARM Preserved).
SH-AHS-0006	Candesartan cilexetil (candesartan) in heart failure assessment of reduction in mortality and morbidity (CHARM) Study of candesartan in patients with heart failure who are treated with ACE inhibitors and have depressed left ventricular systolic function (CHARM Added).
SH-AHS-0003	Candesartan cilexetil (candesartan) in heart failure assessment of reduction in mortality and morbidity (CHARM) Clinical study of candesartan in patients with heart failure who are ACE inhibitor intolerant and have depressed left ventricular systolic function (CHARM Alternative).
D2456C00001	A Double Blind, Randomised, 3-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil/Hydrochlorothiazide 32/12.5 mg and 32/25 mg in Comparison with Candesartan Cilexetil 32 mg Alone in Patients with Inadequate Blood Pressure Control on Monotherapy with Candesartan Cilexetil 32 mg
D2451C00261	A Dose-Ranging and Safety Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 6 to <17 Years of Age: A 4-Week, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study